






**C****(a)****(b)****D****(a)****(b)**

**Supplementary Figure S1.** Antiviral effects of lucidone in combination with (A) IFN- $\alpha$ , (B) telaprevir, (C) BMS-790052, or (D) PSI-7977. (a) The traditional isobologram for two agents. The combination effects are analyzed by using CalcuSyn program, in which the lines represent the EDs of the effects of the two compounds to achieve 50, 75, or 90% inhibition. The dots are the actual experimental doses used to achieve those effects. (b) The median-effect analysis. The CI value calculated from each combination data is plotted as the solid line versus the percent inhibition (i.e., the fractional effect). The 95% confidence intervals (1.96 standard deviations) of the CI are shown as two curved dotted lines. The theoretic additive effect (CI = 1) is represented by a straight dotted line. The graphs represent results from triplicate experiments



<b>Lucidone (<math>\mu</math> M)</b>	-	<b>50</b>	<b>50</b>	<b>50</b>	<b>50</b>
<b>IFN (U/ml)</b>	-	<b>60</b>	-	-	-
<b>Telaprevir (<math>\mu</math> M)</b>	-	-	<b>0.6</b>	-	-
<b>BMS-790052 (pM)</b>	-	-	-	<b>8</b>	-
<b>PSI-7977 (nM)</b>	-	-	-	-	<b>80</b>

**Supplementary Figure S2.** Cytotoxicity analysis of lucidone in combination with IFN- $\alpha$ , telaprevir, BMS-790052, or PSI-7977 at higher concentrations. After 3 days, cellular toxicity was evaluated by the MTS assay. The results are expressed as the mean values  $\pm$  SD for triplicate experiments. The error bars denote SD of the mean.